What is HC Wainwright’s Forecast for Indivior Q2 Earnings?

Indivior PLC (NASDAQ:INDV) – HC Wainwright issued their Q2 2026 EPS estimates for shares of Indivior in a research note issued to investors on Monday, January 12th. HC Wainwright analyst B. Folkes forecasts that the company will earn $0.74 per share for the quarter. HC Wainwright has a “Buy” rating and a $48.00 price objective on the stock. The consensus estimate for Indivior’s current full-year earnings is $1.22 per share. HC Wainwright also issued estimates for Indivior’s Q3 2026 earnings at $0.75 EPS, Q4 2026 earnings at $0.79 EPS and FY2030 earnings at $3.77 EPS.

Other research analysts have also issued reports about the company. Northland Securities set a $40.00 target price on Indivior in a research report on Friday, October 31st. Zacks Research upgraded Indivior from a “hold” rating to a “strong-buy” rating in a report on Monday, November 3rd. Morgan Stanley reiterated an “overweight” rating and issued a $36.00 target price on shares of Indivior in a research note on Wednesday, December 3rd. Craig Hallum reissued a “buy” rating and issued a $41.00 target price on shares of Indivior in a research report on Friday, October 31st. Finally, Piper Sandler restated an “overweight” rating and set a $41.00 price target (up previously from $27.00) on shares of Indivior in a report on Friday, October 31st. Two investment analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $34.57.

Indivior Trading Down 2.5%

Shares of NASDAQ:INDV opened at $34.56 on Tuesday. The firm has a market cap of $4.32 billion, a price-to-earnings ratio of 37.57 and a beta of 0.75. Indivior has a 1 year low of $7.62 and a 1 year high of $38.00. The business has a fifty day simple moving average of $34.22 and a 200 day simple moving average of $26.19.

Indivior (NASDAQ:INDV) last issued its earnings results on Thursday, October 30th. The company reported $0.72 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.38 by $0.34. Indivior had a net margin of 9.83% and a negative return on equity of 90.79%. The company had revenue of $314.00 million during the quarter, compared to analyst estimates of $257.66 million.

Hedge Funds Weigh In On Indivior

A number of institutional investors have recently made changes to their positions in INDV. Goldman Sachs Group Inc. lifted its position in shares of Indivior by 18.4% during the 1st quarter. Goldman Sachs Group Inc. now owns 8,368,996 shares of the company’s stock worth $79,757,000 after purchasing an additional 1,299,425 shares during the last quarter. Jane Street Group LLC lifted its holdings in shares of Indivior by 2,597.9% during the first quarter. Jane Street Group LLC now owns 995,013 shares of the company’s stock worth $9,327,000 after buying an additional 958,132 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Indivior by 16.0% in the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,820 shares of the company’s stock valued at $71,000 after acquiring an additional 666 shares during the period. State of New Jersey Common Pension Fund D bought a new stake in shares of Indivior in the second quarter valued at approximately $262,000. Finally, Y Intercept Hong Kong Ltd grew its stake in shares of Indivior by 17.4% in the second quarter. Y Intercept Hong Kong Ltd now owns 25,443 shares of the company’s stock worth $375,000 after acquiring an additional 3,769 shares during the last quarter. 60.33% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other news, Director David E. Wheadon bought 1,771 shares of the stock in a transaction that occurred on Monday, January 5th. The shares were acquired at an average cost of $35.39 per share, for a total transaction of $62,675.69. Following the purchase, the director owned 14,395 shares of the company’s stock, valued at $509,439.05. This represents a 14.03% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Keith Humphreys bought 775 shares of the company’s stock in a transaction that occurred on Monday, January 5th. The stock was purchased at an average price of $35.39 per share, for a total transaction of $27,427.25. Following the acquisition, the director directly owned 5,802 shares in the company, valued at approximately $205,332.78. This trade represents a 15.42% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Over the last 90 days, insiders have purchased 4,871 shares of company stock valued at $172,385.

About Indivior

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.